99mTc-MAA scan was performed to detect GI flow and lung shunt fraction (6) .
Prophylactic embolization of aberrant vessels was performed when appropriate.
Treatment Plan
All radioembolization procedures were performed with a glass-based Yttrium-90 device (TheraSphere®, BTG, United Kingdom). This device is currently approved for hepatocellular carcinoma in the United States and liver neoplasia (worldwide) (10) . The method for determining injected activity required to deliver 120 Gy has been published previously (4, 6, 11, 12 
RESULTS

Baseline characteristics
Most patients (63%) were <65 years old at the time of treatment, of whom 59% were male. The majority of patients had an ECOG status of 0 or 1 (96%).
Most patients (70%) had ≤25% of the liver volume involved by tumor. The majority of patients (62%) had liver-only disease, while 38% had limited extrahepatic disease. Eighteen percent of patients had prior hepatic resection, 14% had prior liver ablation and 4% had prior transarterial chemoembolization (TACE) ( Table 1 ).
Prior to Y90 radioembolization, 56% of patients received three cytotoxic chemotherapeutics (5-fluorouracil (5FU), oxaliplatin and irinotecan), while 41% of patients received only one or two of these agents. Fifteen patients (3%) received no cytotoxic chemotherapy prior to Y90. Twenty-two percent of patients received no biologic agents, 56% received one biologic agent and 22% received three biologic agents (Table 2) .
Nearly all patients underwent lobar or selective radioembolization at the first treatment. Only 2% of patients received whole-liver treatment in a single setting.
Y90 Dosimetry & Delivery
The median radiation dose delivered to the liver was 120.2 Gy (range 35-391 Gy). Ninety percent or greater of the dose was delivered in all treatments. Extrahepatic arterial coil embolization was performed in 25% of patients.
Side Effects & Biochemical Toxicities
The most frequent clinical side effects included fatigue (55%), abdominal pain and/or discomfort (34%) and nausea (19%). Vomiting, anorexia and fever occurred in less than 10% of patients (Table 3) . No gastrointestinal ulcers were reported.
Biochemical toxicities of grade 3 or 4, recorded at any time following treatment, included bilirubin (13%), alkaline phosphatase (9%), albumin (8%), aspartate transaminase (AST) (3%) and alanine transaminase (ALT) (<1%) ( Table 4) .
Overall Survival
Two hundred eighty-four patients had died at the time of data compilation.
Survival analysis is provided in Table 5 Time from diagnosis of hepatic metastases to first Y90 was longer in patients who received three cytotoxic chemotherapeutics compared to those who received ≤2 (22.6 vs. 10.9 months, P<0.001). Median OS from first Y90 was shorter for patients who received three cytotoxic chemotherapeutics compared to those who received ≤2 (9.2 vs. 14.7 months, P<0.001). For patients without extra-hepatic disease at the time of first Y90, median OS was longer for patients receiving ≤2 compared to three cytotoxic chemotherapeutics (16.5 vs. 13.1 months, P<0.05). For patients with extra-hepatic disease at first Y90, median OS was longer for patients receiving ≤2 compared to three cytotoxic chemotherapeutics (9.6 vs. 5.4 months, P=0.003).
Median OS from first Y90 was not significantly different for patients who received no biologic agents compared to those who received one (11.5 vs. 12.9 months). Median OS from first Y90 was longer for patients who received ≤1 biologic agents compared to those who received ≥2 (12.9 vs. 7.0 months, P<0.001). Nonetheless, a significant number of patients undergo Y90 radioembolization of colorectal liver metastases with glass microspheres. The results of this multiinstitutional review of 531 patients with colorectal liver metastases treated with Y90 radioembolization using glass microspheres underscore the consistent, reproducible and favorable survival outcomes of the therapy in the salvage setting. The data show that radioembolization using glass microspheres provides reliable dose delivery, and that the treatment is safe and well tolerated.
Once colorectal liver metastases become chemorefractory, patients' median overall survival approaches four to five months (15) (16) (17) . In addition to the studies cited previously, a number of recent large cohort studies have reported the survival of patients undergoing Y90 radioembolization in the salvage setting.
The survival data from these studies are remarkably consistent and nearly identical to our own findings. Median overall survival from first Y90 treatment in our cohort was 10.6 months. In the next largest published study of 302 patients with chemorefractory colorectal liver metastases using resin microspheres, 
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